Pinned Tweet
GLP-1 drugs in #IBD are a hot talking point at the moment - and they're throwing up some interesting findings, to boot.
We've just had a VERY special expert guest confirmed for our podcast hot seat on this one! 🤩 So please do send us your questions on this topic. Thanks.
The Bottom Line IBD retweeted
🎙️ New @UEGJournal podcast:
Is self-reported gluten sensitivity really about gluten? 🌾
@MohsenSubhani & @MMEstevinho talk with Imran Aziz about the article on non-coeliac gluten sensitivity & its links to disorders of gut-brain interaction.
🎧 bit.ly/4ssWDDA
ALT A smiling man wearing glasses stands in front of a white wall with artwork, with pink audio waves overlaid and text reading "Episode 14: Self-Reported Non-Coeliac Gluten Sensitivity and Disorders of Gut-Brain Interaction with Imran Aziz" and the logo "ueg journal."
The Bottom Line IBD retweeted
🤝 IL-23 + TNF in a single injection: can combination therapy break the efficacy ceiling in refractory IBD?
📍 DUET-CD (n=693) and DUET-UC (n=572): JNJ-4804 (guselkumab + golimumab) vs each drug alone and placebo; ~half had failed ≥2 therapy classes
🎯 Crohn's, week 48 clinical remission: 50.8% vs 42.5% guselkumab vs 25.4% golimumab
🎯 UC, week 48 clinical remission: 41.0% vs 34.0% vs 11.5%
🔥 Failed ≥2 classes: remission ~2× the best comparator in CD and ~60% higher in UC (#UEGWeek2026 subgroup data)
🛡️ Safety in line with each component
👇 The data in one image
🔗 jnj.com/media-center/press-r…
@my_ueg
#MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #UlcerativeColitis
Last call for any questions you may have about fatigue and #IBD or the use of GLP-1 drugs in IBD.
We're recording early next week, so please do let us know if you have any burning questions you'd ike us to ask on the podcast!
podcasts.apple.com/us/podcas…
Maternal Obesity Is Associated With Adverse Pregnancy Outcomes in #IBD ⤵️
"Preconception and antenatal care should treat metabolic health as part of the picture too, alongside better use of aspirin and LMWH where indicated" - @jennie_clough
onlinelibrary.wiley.com/doi/…
The Bottom Line IBD retweeted
💊 Obefazimod holds the line in UC.
📍 ABTECT-Maintenance (phase 3, #UEGWeek2026): 580 induction responders re-randomised for 44 more weeks
🎯 Clinical remission at week 52: 51% on 25 mg AND 50 mg vs 10% placebo
🔬 Endoscopic remission 41–48% vs 10%. Both doses beat placebo on all 8 key endpoints (p<0.0001)
🔁 Works after advanced-therapy failure too: 34–42% vs 7% remission
⚠️ Any AE 50% / 58% / 72%; 2 non-skin cancers on 50 mg, judged unlikely related
👇 The full maintenance data in one image
🔗 ir.abivax.com/news-releases/…
@my_ueg
#MedTwitter #GITwitter #MedEd #IBD #UlcerativeColitis #Obefazimod
The Bottom Line IBD retweeted
💊 Vedolizumab's mechanism… in a once-daily pill?
📍 SWIFT (phase 2, #UEGWeek2026 late-breaker): emvistegrast, Gilead's oral α4β7 integrin inhibitor, in 238 adults with moderate–severe UC
🎯 Week 12 clinical response (primary): 66% vs 37% placebo (200 mg)
✅ Clinical remission: 31% vs 8%
🔬 Endoscopic improvement: 39% vs 12%
🛡️ AEs 36% vs 37%; serious AEs 2%, none drug-related
⏳ 25 & 75 mg data not yet disclosed; phase 3 planned for 2027
👇 The data in one image
🔗 fiercebiotech.com/biotech/gi…
@my_ueg
#MedTwitter #GITwitter #MedEd #IBD #UlcerativeColitis #OralTherapy
The Bottom Line IBD retweeted
1)Are live vaccines truly off-limits in IBD patients on immune-modifying therapy?
We are taught they’re contraindicated, but rotavirus vaccine appears safe in biologic-exposed infants, and measles outbreaks have put this question in focus. @AmCollegeGastro @UWMadPharmacy
The Bottom Line IBD retweeted
🩺 Perianal fistulas: one of the toughest corners of Crohn's. Finally, a dedicated phase 3 for an IL-23 inhibitor.
📍 FUZION CD (#UEGWeek2026 late-breaker): guselkumab 100 mg q8w or 200 mg q4w vs placebo
🔬 Week 24 combined fistula remission (clinical + blinded MRI): 28% / 27% vs 10% placebo
📈 Week 48: 35% on 100 mg q8w (up from 28%) and 26% on 200 mg q4w
✅ >90% of patients completed treatment to week 48
⚠️ No week-48 placebo data or p-values released yet
👇 The data in one image
🔗 jnj.com/media-center/press-r…
@my_ueg
#MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #PerianalFistula
The Bottom Line IBD retweeted
The surgeon drives, the geriatrician is the airbag.
Screen the #Frail & the #Elderly before #Colorectal MDT - a few minutes of bedside tests - and call the geriatrician if positive. Outcomes will follow!
75'' recap👇 Full lecture by @3isac link below - free until 3 Nov #THRIVE2027
The Bottom Line IBD retweeted
Excited to share our latest publication in @BMJDigitalHealth! 🚀
In just 6 months, @ChatIBDapp reached 913 users across 69 countries, generating 7,222 messages in 28 languages 🌍
A first step towards guideline-grounded AI in #IBD care. Formal validation is next!
Congrats to @drshaunchuah the brilliant mind behind this and to Nik Plevris
doi.org/10.1136/bmjcdh-2026-…
The Bottom Line IBD retweeted
Is proximal small bowel Crohn worse than distal bcs the Tx is less effective there?
Well, No...
In our @sheba_medical #capsule study now published in @AGA_CGH , biologics induced similar mucosal healing in proximal vs distal SB.
@OffirU @HelmsleyTrust
cghjournal.org/article/S1542…
The Bottom Line IBD retweeted
🎯 STRIDE-III is here!
The new treat-to-target framework for #IBD, presented at #UEGWeek2026 and published in @LancetGastroHep.
🔑 The big shift: not every target asks for the same thing.
🔴 Actionable → miss it, change treatment
🟡 Adjunctive (NEW) → histology in UC, transmural healing in CD, urgency: optimise & monitor
🟢 Patient-centred → fatigue, disability, QoL: shared decisions
📊 1,018 studies · modified Delphi · ≥75% agreement
👇 The whole framework in one image
🔗 doi.org/10.1016/S2468-1253(2…
@myueg
#MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #UlcerativeColitis
The Bottom Line IBD retweeted
🎯 Should we treat UC all the way to histology? VERDICT says... maybe not!
📍 672 adults with moderate–severe UC on vedolizumab, randomised to 3 treat-to-target strategies (#UEGWeek2026 late-breaker)
🔬 Reaching disease clearance (symptoms + endoscopy + histology) → 67% lower risk of UC complications vs a symptom-only target
📉 HR 0.33 (95% CI 0.17–0.67), p=0.0014
🤔 Endoscopic target vs full clearance: no difference (HR 1.10)
⚠️ Analysis only includes patients who reached their target (59.5%)
👇 The whole trial in one image
🔗 takeda.com/newsroom/newsrele…
@my_ueg
#MedTwitter #GITwitter #MedEd #IBD #UlcerativeColitis #TreatToTarget
Pleased to say that Nigel & I now have a confirmed recording date for our fatigue in IBD podcast episode. Sorry this one took so long!
Then we're off on a virtual visit to the US to record the next trio: GLP-1s in IBD (massive interest right now); pain management; and IBD Qorus.
The Bottom Line IBD retweeted
A welcome step forward in Crohn’s disease care!
I am excited about the FDA approval of subcutaneous induction with risankizumab (SKYRIZI) for Crohn’s disease.
Having cared for patients with IBD for many years, I have seen how the burden of treatment extends well beyond the disease itself. Traveling to infusion centers, taking time away from work, arranging transportation, and balancing treatment with everyday life can be challenging.
The ability to initiate treatment at home offers patients something valuable: greater flexibility, convenience, and potentially more control over their treatment journey.
The encouraging clinical and endoscopic outcomes from the AFFIRM trial make this development even more meaningful.
Of course, convenience must be accompanied by efficacy, safety, affordability, and access.
I see this as another positive step toward making effective IBD care fit better into patients’ lives, rather than asking patients to continually rearrange their lives around treatment.
Innovation in IBD should not only improve outcomes. It should also improve the patient experience.
#IBD #CrohnsDisease #SKYRIZI #PatientCenteredCare #IBDLibrary
linkedin.com/posts/ibd-libra…
The Bottom Line IBD retweeted
What changes from STRIDE-II to STRIDE-III? Presented at #UEGWeek2026
• Targets split into actionable, adjunctive & patient-centred
• FC: <200 µg/g; <100 for deeper control
• Urgency and fatigue now included
• Adapted tools for resource-limited settings
#IBD #weareUEG
🤖 Made with AI
The Bottom Line IBD retweeted
For latest episode of our “Wrestling The Octopus IBD” podcast we were joined by Sue Blackwell @littlemissileo a UC patient who, through involvement with research, recently gained a PhD on parastomal hernias. We talked about #stomas, J pouches & #GLP1, amongst others things
The Bottom Line IBD retweeted
In 2000, a flood in Walkerton, Canada contaminated the water and sickened an entire town. It was a revealing example of the gut-brain axis in action.
psychologytoday.com/us/blog/…
The Bottom Line IBD retweeted
🧠 Stay informed in digestive health with the UEG Newsletter.
Get:
✔ Expert insights & research
✔ Educational content
✔ Career opportunities
✔ UEG news & events
📩 Subscribe today: ueg.eu/p/222
ALT a black tablet with a green alligator on it
The Bottom Line IBD retweeted
Could where body fat is stored help identify fracture risk in people with IBD? Read the paper by Suntharalingam et al. on “Regional fat distribution as a novel predictor of fracture risk in IBD…” via bit.ly/4AnT6Kg #BMJOG #BMJOGPapers @ChristianSelin3
